Development of Clinically Optimized Sitagliptin and Dapagliflozin Complex Tablets: Pre-Formulation, Formulation, and Human Bioequivalence Studies

The purpose of this study is to derive an optimal drug release formulation with human clinical bioequivalence in developing a sitagliptin phosphate monohydrate-dapagliflozin propanediol hydrate fixed-dose combination (FDC) tablet as a treatment for type 2 diabetes mellitus. As a treatment for type 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, So-Jin, Kim, Joo-Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141516/
https://www.ncbi.nlm.nih.gov/pubmed/37111730
http://dx.doi.org/10.3390/pharmaceutics15041246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141516/
https://www.ncbi.nlm.nih.gov/pubmed/37111730
http://dx.doi.org/10.3390/pharmaceutics15041246

Ejemplares similares